Personalized mRNA vaccine induces strong, durable immunity in hard-to-treat breast cancer
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: In an experimental trial, a personalized mRNA vaccine was tested in 14 individuals with an aggressive form of breast cancer. It trained immune cells to target cancer-specific mutant proteins, inducing strong, lasting immunity. Ten participants remained disease-free. Analysis of relapses revealed resistance mechanisms, offering essential insights for future therapies. T cells targeting cancer-specific mutant proteins remained in treated individuals years after vaccination.
Source: Nature
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
OpenAlex ID: W7130423449